Canine RAGE Antibody

Catalog #: AF4750 Datasheet

Catalog #	Availability	Size / Price	Qty
AF4750
AF4750-SP

All RAGE/AGER Antibodies

Product Details

FAQs

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Canine RAGE Antibody Summary

Species Reactivity

Canine

Specificity

Detects canine RAGE in ELISAs and Western blots. In sandwich immunoassays, approximately 0.5% cross‑reactivity with recombinant human RAGE is observed and less than 0.1% cross-reactivity with recombinant mouse RAGE and recombinant rat RAGE is observed.

Source

Polyclonal Sheep IgG

Purification

Antigen Affinity-purified

Immunogen

Mouse myeloma cell line NS0-derived recombinant canine RAGE
Asp25-Val339
Accession # XP_532093

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Canine RAGE (Catalog # 4750-RG)

Canine RAGE Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

0.2-0.8 µg/mL

Use in combination with:

Detection Reagent: Canine RAGE Biotinylated Antibody (Catalog # BAF4750)

Standard: Recombinant Canine RAGE Protein, CF (Catalog # 4750-RG)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: RAGE/AGER

Advanced glycation endproducts (AGEs) are adducts formed by the non-enzymatic glycation of macromolecules. AGE formation is accelerated in oxidative and hyperglycemic conditions, diabetes, renal failure, atherosclerosis, Alzheimer’s disease, arthritis, and in normal aging (1‑5). Receptor for advanced glycation endproducts (RAGE) is a 35 kDa type I transmembrane protein belonging the immunoglobulin superfamily. Besides AGEs, RAGE binds beta -amyloid peptide, S100/calgranulin family proteins, HMGB1/amphoterin, and leukocyte integrins (6‑9). Mature canine RAGE consists of a 383 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain and two Ig-like C‑type domains, a 23 aa transmembrane segment, and a 43 aa cytoplasmic domain (10). Within the ECD, canine RAGE shares 73%‑77% aa sequence identity with human, mouse, and rat RAGE. In human, soluble forms of RAGE are generated by alternate splicing and are associated with multiple disease states (11, 12). RAGE is expressed in the embryonic central nervous system and on macrophages, monocytes, smooth muscle cells, and endothelial cells (13‑15). It is upregulated in response to AGE accumulation, and its activation induces a broad proinflammatory response (6, 15). The increased production of reactive oxygen species during inflammation promotes additional AGE formation and RAGE upregulation, a cycle that exacerbates diabetic complications and inflammation‑induced tissue injury (2, 4).

References

Schleicher, E. and U. Friess (2007) Kidney Int. Suppl. 106:S17.
Herold, K. et al. (2007) J. Leukoc. Biol. 82:204.
Thornalley, P.J. (2006) J. Ren. Nutr. 16:178.
Goldin, A. et al. (2006) Circulation 114:597.
Ramasamy, R. et al. (2005) Glycobiology 15:16R.
Kislinger, T. et al. (1999) J. Biol. Chem. 274:31740.
Yan, S.D. et al. (1996) Nature 382:685.
Huttenen, H. et al. (2000) J. Biol. Chem. 275:40096.
Chavakis, T. et al. (2003) J. Exp. Med. 198:1507.
Murua Escobar, H. et al. (2006) Gene 369:45.
Yonekura H, et al. (2003) Biochem. J. 370:1097.
Koyama, H. et al. (2007) Mol. Med. 13:625.
Hori, O. et al. (1995) J. Biol. Chem. 270:25752.
Brett, J. et al. (1993) Am. J. Pathol. 143:1699.
Bierhaus, A. et al. (2006) Curr. Opin. Investig. Drugs 7:985.

Long Name

Receptor for Advanced Glycation End Products

Entrez Gene IDs

177 (Human); 11596 (Mouse); 81722 (Rat); 403168 (Canine)

Alternate Names

advanced glycosylation end product-specific receptor; AGER; RAGE isoform delta; RAGE isoform sRAGE-delta; RAGE; Receptor for advanced glycosylation end products; receptor for advanced glycosylation end-products; SCARJ1